Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy

Calcified Tissue International

Volumn 83, Issue 2, 2008, Pages 85-92

  Fogelman, I ^a   Fordham, J N ^b   Fraser, W D ^c   Spector, T D ^d   Christiansen, C ^e   Morris, S A ^f   Fox, J ^f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e NORDIC BIOSCIENCE A S   (Denmark)

^f NPS Pharmaceuticals   (United States)

Author keywords

Bone mineral density; Bone turnover marker; Hormone replacement therapy; Parathyroid hormone (1 84) therapy; Postmenopausal osteoporosis

Indexed keywords

CITRATE CALCIUM; COLECALCIFEROL; ESTROGEN; PARATHYROID HORMONE; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIP; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PARATHYROID HORMONE THERAPY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

BONE DENSITY; BONE REMODELING; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PROGESTINS; SPINAL FRACTURES;

EID: 51449096873     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-008-9152-3     Document Type: Article

References (20)

1. U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General
2. National Osteoporosis Foundation (2003) Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington DC
3. AB Hodsman DC Bauer DW Dempster L Dian DA Hanley ST Harris DL Kendler MR McClung PD Miller WP Olszynski E Orwoll CK Yuen 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use Endocr Rev 26 688 703
4. CJ Hernandez GS Beaupre R Marcus DR Carter 2001 A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment Bone 29 511 516
5. P Roschger S Rinnerthaler J Yates GA Rodan P Fratzl K Klaushofer 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Bone 29 185 191
6. R Marcus M Wong H Heath III JL Stock 2002 Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint Endocr Rev 23 16 37
7. JN Bradbeer ME Arlot PJ Meunier J Reeve 1992 Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone Clin Endocrinol (Oxf) 37 282 289
8. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich J-Y Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441
9. SL Greenspan HG Bone MP Ettinger DA Hanley R Lindsay JR Zanchetta CM Blosch AL Mathisen SA Morris TB Marriott 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 326 339
10. JS Finkelstein A Hayes JL Hunzelman JJ Wyland H Lee RM Neer 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 1216 1226
11. DM Black SL Greenspan KE Ensrud L Palermo JA McGowan TF Lang P Garnero ML Bouxsein JP Bilezikian CJ Rosen 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 1207 1215
12. C Deal M Omizo EN Schwartz EF Eriksen P Cantor J Wang EV Glass SL Myers JH Krege 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial J Bone Miner Res 20 1905 1911
13. R Lindsay J Nieves C Formica E Henneman L Woelfert V Shen D Dempster F Cosman 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis Lancet 350 550 555
14. F Cosman J Nieves L Woelfert C Formica S Gordon V Shen R Lindsay 2001 Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal J Bone Miner Res 16 925 931
15. European Agency for the Evaluation of Medicinal Products (2003) EMEA public statement on recent publications regarding hormone replacement therapy. http://www.emasonline.org/content/EMEA/EMEA_3_12_2003.pdf
16. HK Genant CY Wu C van Kuijk MC Nevitt 1993 Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 8 1137 1148
17. B Ettinger J San Martin G Crans I Pavo 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 745 751
18. JA Gasser P Ingold A Venturiere JR Green 2006 Chronic subcutaneous, but not single intravenous dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH J Bone Miner Res 21 Suppl 1 S113
19. D O'Connell J Robertson D Henry W Gillespie 1998 A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects Climacteric 1 112 123
20. JP Bilezekian SL Greenspan DM Black DE Sellmeyer K Ensrud CJ Rosen J Fox 2006 Concomitant administration of alendronate blunts the acute calcemic response to recombinant human parathyroid hormone 1-84: results from a PaTH substudy Osteoporos Int 17 Suppl 2 S85